Products You May Like
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES
VANCOUVER, British Columbia, Could 28, 2021 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the “Firm”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU ) is happy to announce the closing of its bought-deal public providing pursuant to which the Firm issued 15,812,500 models of the Firm (the “Items”) at a value of $0.40 per Unit for combination gross proceeds to the Firm of $6,325,000 (the “Providing”), together with the complete train of the over-allotment possibility. The Providing was led by Analysis Capital Company as the only real underwriter and sole bookrunner (the “Underwriter”).
Every Unit consists of 1 widespread share within the capital of the Firm (a “Frequent Share”) and one Frequent Share buy warrant of the Firm (a “Warrant“). Every Warrant entitles the holder thereof to buy one Frequent Share at an train value of $0.50 at any time as much as 36 months from the closing of the Providing.
The online proceeds from the Providing shall be utilized by the Firm for the needs described within the prospectus complement of the Firm dated Could 25, 2021, which dietary supplements the quick type base shelf prospectus of the Firm dated April 26, 2021.
This press launch will not be a suggestion to promote or the solicitation of a suggestion to purchase the securities in the USA or in any jurisdiction wherein such provide, solicitation or sale could be illegal previous to qualification or registration beneath the securities legal guidelines of such jurisdiction. The securities being supplied haven’t been, nor will they be, registered beneath the USA Securities Act of 1933, as amended, and such securities might not be supplied or offered inside the USA or to, or for the account or advantage of, U.S. individuals absent registration or an relevant exemption from U.S. registration necessities and relevant U.S. state securities legal guidelines.
About BetterLife Pharma Inc.
BetterLife Pharma Inc. is an rising biotechnology firm engaged within the growth and commercialization of subsequent era psychedelic merchandise for the therapy of psychological issues. Using drug supply platform applied sciences, BetterLife can also be refining and creating drug candidates from a broad set of complementary interferon-based applied sciences which have the potential to have interaction the immune system to battle virus infections, such because the coronavirus illness (COVID-19) and human papillomavirus.
For additional info please go to www.abetterlifepharma.com.
Contact
Ahmad Doroudian, Chief Government Officer
E mail: Ahmad.Doroudian@blifepharma.com
Cellphone: (604) 221-0595
Cautionary Word Relating to Ahead-Wanting Statements
No securities alternate has reviewed nor accepts duty for the adequacy or accuracy of the content material of this information launch. This information launch comprises forward-looking statements referring to product growth, licensing, commercialization and regulatory compliance points and different statements that aren’t historic information. Ahead-looking statements are sometimes recognized by phrases resembling “will”, “could”, “ought to”, “anticipate”, “expects” and comparable expressions. All statements aside from statements of historic reality, included on this launch are forward-looking statements that contain dangers and uncertainties. There may be no assurance that such statements will show to be correct and precise outcomes and future occasions may differ materially from these anticipated in such statements. Necessary components that might trigger precise outcomes to vary materially from the Firm’s expectations embrace the failure to fulfill the circumstances of the related securities alternate(s) and different dangers detailed on occasion within the filings made by the Firm with securities laws. The reader is cautioned that assumptions used within the preparation of any forward-looking info could show to be incorrect. Occasions or circumstances could trigger precise outcomes to vary materially from these predicted, on account of quite a few identified and unknown dangers, uncertainties, and different components, a lot of that are past the management of the Firm. The reader is cautioned to not place undue reliance on any forward-looking info. Such info, though thought of cheap by administration on the time of preparation, could show to be incorrect and precise outcomes could differ materially from these anticipated. Ahead-looking statements contained on this information launch are expressly certified by this cautionary assertion. The forward-looking statements contained on this information launch are made as of the date of this information launch and the Firm will replace or revise publicly any of the included forward-looking statements as expressly required by relevant regulation.
